OncoMatch/Clinical Trials/NCT05136846
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Is NCT05136846 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for locally advanced lung non-small cell carcinoma.
Treatment: Carboplatin · Durvalumab · Paclitaxel · Papaverine · Pemetrexed — This phase I trial finds out the best dose, possible benefits and/or side effects of papaverine when given together with chemoradiation intreating patients with stage II-III non-small cell lung cancer. Papaverine targets mitochondrial metabolism to decrease the cancer growth process. Giving papaverine with chemoradiation may work best to treat patients with non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage II, IIA, IIB, III, IIIA, IIIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: No prior radiation therapy which would result in overlapping radiation fields
History of previous radiation therapy which would result in overlapping radiation fields
Cannot have received: nitrates or nitroglycerin
Patients who are presently receiving nitrates or nitroglycerin, or have received these medications within 30 days of day 1 of protocol treatment
Cannot have received: Sildenafil (Sildenafil)
Exception: Must discontinue use for 2 days prior to initiation of papaverine, during the duration of study, and for 2 days after last dose of papaverine
Patients who are currently taking Sildenafil should agree to discontinue use for 2 days prior to initiation of papaverine, during the duration of study, and for 2 days after last dose of papaverine
Lab requirements
Blood counts
Absolute neutrophil count >=1.5 x 10^9/L; Hemoglobin >= 9 g/dL; Platelets >= 100 x 10^9/L
Kidney function
Creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min or 24-hour urine creatinine clearance >= 50 mL/min
Liver function
Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN
Absolute neutrophil count >=1.5 x 10^9/L; Hemoglobin >= 9 g/dL; Platelets >= 100 x 10^9/L; Total bilirubin <= 1.5 x ULN; AST and ALT <= 2.5 x ULN; Creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 mL/min or 24-hour urine creatinine clearance >= 50 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify